Joseph P Antonios1, Horacio Soto1, Richard G Everson1, Diana Moughon2, Joey R Orpilla1, Namjo P Shin1, Shaina Sedighim1, Janet Treger1, Sylvia Odesa1, Alexander Tucker1, William H Yong3, Gang Li4, Timothy F Cloughesy5,6,7, Linda M Liau1,5,6, Robert M Prins1,5,6,8. 1. Department of Neurosurgery, David Geffen School of Medicine at UCLA, University of California, Los Angeles, California, USA. 2. Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California, USA. 3. Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, University of California, Los Angeles, California, USA. 4. Department of Biostatistics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, California, USA. 5. Brain Research Institute, David Geffen School of Medicine at UCLA, University of California, Los Angeles, California, USA. 6. Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California, Los Angeles, California, USA. 7. Department of Neurology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, California, USA. 8. Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, California, USA.
Abstract
Background: Adaptive immune resistance in the tumor microenvironment appears to attenuate the immunotherapeutic targeting of glioblastoma (GBM). In this study, we identified a tumor-infiltrating myeloid cell (TIM) population that expands in response to dendritic cell (DC) vaccine treatment. The aim of this study was to understand how this programmed death ligand 1 (PD-L1)-expressing population restricts activation and tumor-cytolytic function of vaccine-induced tumor-infiltrating lymphocytes (TILs). Methods: To test this hypothesis in our in vivo preclinical model, we treated mice bearing intracranial gliomas with DC vaccination ± murine anti-PD-1 monoclonal antibody (mAb) blockade or a colony stimulating factor 1 receptor inhibitor (CSF-1Ri) (PLX3397) and measured overall survival. We then harvested and characterized the PD-L1+ TIM population and its role in TIL activation and tumor cytolysis in vitro. Results: Our data indicated that the majority of PD-L1 expression in the GBM environment is contributed by TIMs rather than by tumor cells themselves. While PD-1 blockade partially reversed the TIL dysfunction, targeting TIMs directly with CSF-1Ri altered TIM expression of key chemotactic factors associated with promoting increased TIL infiltration after vaccination. Neither PD-1 mAb nor CSF-1Ri had a demonstrable therapeutic benefit alone, but when combined with DC vaccination, a significant survival benefit was observed. When the tripartite regimen was given (DC vaccine, PD-1 mAb, PLX3397), long-term survival was noted together with an increase in the number of TILs and TIL activation. Conclusion: Together, these studies elucidate the role that TIMs play in mediating adaptive immune resistance in the GBM microenvironment and provide evidence that they can be manipulated pharmacologically with agents that are clinically available. Development of immune resistance in response to active vaccination in GBM can be reversed with dual administration of CSF-1Ri and PD-1 mAb.
Background: Adaptive immune resistance in the tumor microenvironment appears to attenuate the immunotherapeutic targeting of glioblastoma (GBM). In this study, we identified a tumor-infiltrating myeloid cell (TIM) population that expands in response to dendritic cell (DC) vaccine treatment. The aim of this study was to understand how this programmed death ligand 1 (PD-L1)-expressing population restricts activation and tumor-cytolytic function of vaccine-induced tumor-infiltrating lymphocytes (TILs). Methods: To test this hypothesis in our in vivo preclinical model, we treated mice bearing intracranial gliomas with DC vaccination ± murine anti-PD-1 monoclonal antibody (mAb) blockade or a colony stimulating factor 1 receptor inhibitor (CSF-1Ri) (PLX3397) and measured overall survival. We then harvested and characterized the PD-L1+ TIM population and its role in TIL activation and tumor cytolysis in vitro. Results: Our data indicated that the majority of PD-L1 expression in the GBM environment is contributed by TIMs rather than by tumor cells themselves. While PD-1 blockade partially reversed the TIL dysfunction, targeting TIMs directly with CSF-1Ri altered TIM expression of key chemotactic factors associated with promoting increased TIL infiltration after vaccination. Neither PD-1 mAb nor CSF-1Ri had a demonstrable therapeutic benefit alone, but when combined with DC vaccination, a significant survival benefit was observed. When the tripartite regimen was given (DC vaccine, PD-1 mAb, PLX3397), long-term survival was noted together with an increase in the number of TILs and TIL activation. Conclusion: Together, these studies elucidate the role that TIMs play in mediating adaptive immune resistance in the GBM microenvironment and provide evidence that they can be manipulated pharmacologically with agents that are clinically available. Development of immune resistance in response to active vaccination in GBM can be reversed with dual administration of CSF-1Ri and PD-1 mAb.
Authors: Scott N Gettinger; Leora Horn; Leena Gandhi; David R Spigel; Scott J Antonia; Naiyer A Rizvi; John D Powderly; Rebecca S Heist; Richard D Carvajal; David M Jackman; Lecia V Sequist; David C Smith; Philip Leming; David P Carbone; Mary C Pinder-Schenck; Suzanne L Topalian; F Stephen Hodi; Jeffrey A Sosman; Mario Sznol; David F McDermott; Drew M Pardoll; Vindira Sankar; Christoph M Ahlers; Mark Salvati; Jon M Wigginton; Matthew D Hellmann; Georgia D Kollia; Ashok K Gupta; Julie R Brahmer Journal: J Clin Oncol Date: 2015-04-20 Impact factor: 44.544
Authors: Robert M Prins; Horacio Soto; Vera Konkankit; Sylvia K Odesa; Ascia Eskin; William H Yong; Stanley F Nelson; Linda M Liau Journal: Clin Cancer Res Date: 2010-12-06 Impact factor: 12.531
Authors: Linda M Liau; Robert M Prins; Sylvia M Kiertscher; Sylvia K Odesa; Thomas J Kremen; Adrian J Giovannone; Jia-Wei Lin; Dennis J Chute; Paul S Mischel; Timothy F Cloughesy; Michael D Roth Journal: Clin Cancer Res Date: 2005-08-01 Impact factor: 12.531
Authors: Joseph P Antonios; Horacio Soto; Richard G Everson; Joey Orpilla; Diana Moughon; Namjo Shin; Shaina Sedighim; William H Yong; Gang Li; Timothy F Cloughesy; Linda M Liau; Robert M Prins Journal: JCI Insight Date: 2016-07-07
Authors: Richard G Everson; Joseph P Antonios; Dominique N Lisiero; Horacio Soto; Rudi Scharnweber; Matthew C Garrett; William H Yong; Ning Li; Gang Li; Carol A Kruse; Linda M Liau; Robert M Prins Journal: Neuro Oncol Date: 2015-09-01 Impact factor: 12.300
Authors: Stephanie M Pyonteck; Leila Akkari; Alberto J Schuhmacher; Robert L Bowman; Lisa Sevenich; Daniela F Quail; Oakley C Olson; Marsha L Quick; Jason T Huse; Virginia Teijeiro; Manu Setty; Christina S Leslie; Yoko Oei; Alicia Pedraza; Jianan Zhang; Cameron W Brennan; James C Sutton; Eric C Holland; Dylan Daniel; Johanna A Joyce Journal: Nat Med Date: 2013-09-22 Impact factor: 53.440
Authors: Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas Journal: Nature Date: 2014-11-27 Impact factor: 49.962
Authors: Joseph A Flores-Toro; Defang Luo; Adithya Gopinath; Matthew R Sarkisian; James J Campbell; Israel F Charo; Rajinder Singh; Thomas J Schall; Meenal Datta; Rakesh K Jain; Duane A Mitchell; Jeffrey K Harrison Journal: Proc Natl Acad Sci U S A Date: 2019-12-26 Impact factor: 11.205
Authors: Abhishek D Garg; Lien Vandenberk; Matthias Van Woensel; Jochen Belmans; Marco Schaaf; Louis Boon; Steven De Vleeschouwer; Patrizia Agostinis Journal: Oncoimmunology Date: 2017-03-03 Impact factor: 8.110
Authors: Tom B Davidson; Alexander Lee; Melody Hsu; Shaina Sedighim; Joey Orpilla; Janet Treger; Max Mastall; Saskia Roesch; Carmen Rapp; Mildred Galvez; Aaron Mochizuki; Joseph Antonios; Alejandro Garcia; Nikesh Kotecha; Nicholas Bayless; David Nathanson; Anthony Wang; Richard Everson; William H Yong; Timothy F Cloughesy; Linda M Liau; Christel Herold-Mende; Robert M Prins Journal: Clin Cancer Res Date: 2018-11-29 Impact factor: 12.531
Authors: Joseph P Antonios; Horacio Soto; Richard G Everson; Diana L Moughon; Anthony C Wang; Joey Orpilla; Caius Radu; Benjamin M Ellingson; Jason T Lee; Timothy Cloughesy; Michael E Phelps; Johannes Czernin; Linda M Liau; Robert M Prins Journal: Proc Natl Acad Sci U S A Date: 2017-09-05 Impact factor: 11.205
Authors: Jianfeng Shen; Wei Zhao; Zhenlin Ju; Lulu Wang; Yang Peng; Marilyne Labrie; Timothy A Yap; Gordon B Mills; Guang Peng Journal: Cancer Res Date: 2018-11-27 Impact factor: 12.701
Authors: Stephen J Bagley; Wei-Ting Hwang; Steven Brem; Gerald P Linette; Donald M O'Rourke; Arati S Desai Journal: J Neurooncol Date: 2018-10-23 Impact factor: 4.130